Effect of antitubercular drugs on dipalmitoylphosphatidylcholine monolayers: Implications for drug loaded surfactants

Respiratory Physiology and Neurobiology

Volumn 145, Issue 1, 2005, Pages 65-77

  Chimote, G ^a   Banerjee, R ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

Drug DPPC interaction; Pulmonary surfactant system; Tuberculosis

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; ETHAMBUTOL; ISONIAZID; LIPOSOME; LUNG SURFACTANT; RIFAMPICIN; SURFACTANT; TUBERCULOSTATIC AGENT;

ARTICLE; DRUG ADSORPTION; DRUG EFFECT; PARAMETER; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURFACE TENSION; TUBERCULOSIS;

ANALYSIS OF VARIANCE; ANTITUBERCULAR AGENTS; DRUG COMBINATIONS; ETHANOLAMINES; FATTY ACIDS, UNSATURATED; HUMANS; MODELS, MOLECULAR; PULMONARY SURFACTANTS; SURFACE PROPERTIES; TUBERCULOSIS, PULMONARY;

EID: 12344284909     PISSN: 15699048     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resp.2004.10.003     Document Type: Article

References (27)

1. S. Agrawal, I. Singh, K.J. Kaur, S.R. Bhade, C.L. Kaul, and R. Panchagnula Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels Int. J. Pharm. 276 2004 41 49
2. S. Agrawal, I. Singh, K.J. Kaur, S.R. Bhade, C.L. Kaul, and R. Panchagnula Bioequivalence trials of rifampicin containing formulations: extrinsic and intrinsic factors in the absorption of rifampicin Pharmacol. Res. 50 2004 317 327
3. R.L. Auten, R.H. Notter, J. Kendig, M. Davis, and D.L. Sharpiro Surfactant treatment of full-term newborns with respiratory failure Pediatrics 87 1991 101 107
4. R. Banerjee, and J.R. Bellare In vitro evaluation of surfactants with eucalyptus oil for Respiratory Distress Syndrome Respir. Physiol. 126 2001 141 151
5. J.B. Chung, R.E. Shanks, R.E. Hanneman, and E.I. Franses Spinning bubble tensiometry of aqueous dipalmitoylphosphatidylcholine and lung surfactant dispersions Colloids Surf. 43 1990 223 240
6. G. Enhorning Pulsating bubble technique for evaluating pulmonary surfactant J. Appl. Physiol. 43 1977 198 203
7. J. Goerke, and J.A. Clements Alveolar surface tension and lung surfactant A.P. Fishman P.T. Mackelroy J. Mead G.R. Geiger Handbook of Physiology. The Respiratory System. vol. III: Mechanics of Breathing 1986 American Physiology Society Press Bethesda, MD 247 261
8. J.J. Haitsma, M. Lachmann, and B. Lachmann Exogenous surfactant as a drug delivery agent Adv. Drug. Deliv. Rev. 47 2001 197 207
9. S.B. Hall, J.A. Venkitaraman, B.A. Whitsett, Holm, and R.H. Notter Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants Am. Rev. Respir. Dis. 145 1992 24 30
10. A.H. Jobe Pulmonary surfactant therapy N. Engl. J. Med. 328 1993 861 868
11. V.S. Kharash, T.D. Sweeney, J. Fredberg, J. Lehr, A.I. Damokosh, M.A. Avery, and J.D. Brain Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs Am. Rev. Respir. Dis. 144 1991 909 913
12. R. Nagarajan Micellization, mixed micellization and solubilization: the role of interfacial interactions Adv. Coll. Interface Sci. 26 1986 205 264
13. R.H. Notter, and P.E. Morrow Pulmonary surfactant: a surface chemistry viewpoint Ann. Biomed. Eng. 3 1975 119 159
14. R.H. Notter, S.A. Tabak, and R.D. Mavis Surface properties of binary mixtures of some pulmonary surfactant components J. Lipid. Res. 21 1980 10 22
15. R. Pandey, S. Sharma, and G.K. Khuller Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis Int. J. Antimicrob. Agents 23 2004 414 415
16. R. Pandey, A. Zahoor, S. Sharma, and G.K. Khuller Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis Tuberculosis 83 2003 373 378
17. C. Rodrigues, P. Gameiro, M. Prieto, and C. Baltazar Interaction of rifampicin and isoniazid with large unilamellar liposomes: spectroscopic location studies Biochim. Biophys. Acta 1620 2003 151 159
18. G.J. Van Daal, J.A. Bos, E.P. Eijking, D. Gommers, E. Hannappel, and B. Lachmann Surfactant replacement therapy improves pulmonary mechanics in end-stage influenza pneumonia in mice Am. Rev. Respir. Dis. 145 1992 859 863
19. L.M.G. Van Glode, J.J. Batenburg, and B. Robertson The pulmonary surfactant system: biochemical aspects and functional significance Physiol. Rev. 68 1988 374 455
20. A. Veen, D. Gommers, J.W. Mouton, J.A. Kluytmans, E.J. Krijt, and B. Lachmann Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity Br. J. Pharmacol. 118 1996 593 598
21. A. Veen, J.W. Mouton, D. Gommers, J.A. Kluytmans, P. Dekkers, and B. Lachmann Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime and tobramycin Antimicrob. Agents Chemother. 39 1995 329 333
22. A. Veen, J.W. Mouton, D. Gommers, and B. Lachmann Pulmonary surfactant as a vehicle for intratracheally instilled tobramycin in mice infected with Klebsiella pneumoniae Br. J. Pharmacol. 119 1998 1145 1148
23. R.W. Walters, R.R. Jenq, and S.B. Hall Distinct steps in the adsorption of pulmonary surfactant to an air-liquid interface Biophys. J. 78 2000 257 266
24. Z.O. Wang, S.B. Hall, and R.H. Notter Dynamic surface activity of films of lung surfactant phospholipids, hydrophobic proteins, and neutral lipids J. Lipid. Res. 36 1995 1283 1293
25. J.C. Watkins The surface properties of pure phospholipids in relation to those of lung extracts Biochim. Biophys. Acta 152 1968 293 306
26. World Health Organization, 2002. Global Tuberculosis Control. Surveillance, Planning, Financing. WHO Report 2002; Document WHO/CDS/TB/2002.295. Geneva, Switzerland: World Health Organization.
27. S.H. Yu, and F. Possmayer Adsorption, compression and stability of surface films from natural, lipid extract and reconstituted pulmonary surfactants Biochim. Biophys. Acta 1167 1993 264 271